Sangamo cut to Neutral after Hemophilia A ‘about-face’ at Guggenheim

Guggenheim analyst Whitney Ijem downgraded Sangamo to Neutral from Buy after the company reported Q3 earnings and announced that it will not present initial SB-525 in hemophilia A data at ASH in December. The company’s “about-face” on the SB-525 data disclosure is concerning and makes Ijem question the timelines around additional updates, she tells investors. While she understand the company’s desire to wait for a “complete clinical picture” before announcing data, she worries that it might be a moving target for hemophilia A and potentially other programs, Ijem added. She withdrew her prior $18 price target on Sangamo as she awaits more clarity on what can be expected from the company in 2019.
https://thefly.com/landingPageNews.php?id=2821515